We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Juvenile idiopathic arthritis and malignancy.
- Authors
Ruperto, Nicolino; Martini, Alberto
- Abstract
Biologic agents represent a major advance in the treatment of JIA. In 2008 a US Food and Drug Administration (FDA) warning raised the hypothesis that anti-TNF therapies may be associated with an increased incidence of malignancies in children. More recent data seem to suggest that JIA itself, as in the case of RA, is associated with an increased risk of malignancy and that this risk is not further increased with anti-TNF treatment. However, only long-term prospective data on a very large number of patients will provide a definite answer. This article summarizes the current evidence in order to help health professionals properly advise patients and their families about the possible risk of malignancies in JIA treated with biologic agents.
- Subjects
BIOTHERAPY; LYMPHOMA risk factors; TUMOR risk factors; JUVENILE idiopathic arthritis; TUMOR necrosis factors; UNITED States. Food &; Drug Administration; INFLIXIMAB; ETANERCEPT; RESEARCH bias; ABATACEPT; CHEMICAL inhibitors; DISEASE complications
- Publication
Rheumatology, 2014, Vol 53, Issue 6, p968
- ISSN
1462-0324
- Publication type
Article
- DOI
10.1093/rheumatology/ket318